Razpipadon
Clinical data | |
---|---|
Other names | CVL-871; PF-06669571; PW-0464 |
Routes of administration | Oral administration |
Drug class | Dopamine receptor agonist |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
UNII | |
ChEMBL | |
Chemical and physical data | |
Formula | C19H17F2N3O4 |
Molar mass | 389.359 g·mol−1 |
3D model (JSmol) | |
| |
|
Razpipadon (developmental code names CVL-871, PF-06669571, PW-0464) is a dopamine receptor agonist which is under development for the treatment of dementia-related apathy.[1][2][3][4] It was originated by Pfizer and is under development by Cerevel Therapeutics.[1] Razpipadon acts as a selective partial agonist of the dopamine D1 and D5 receptors.[1][2][5] It is taken via oral administration.[1] As of April 2022, razpipadon is in phase 2 clinical trials for dementia-related apathy.[1]
See also
[edit]References
[edit]- ^ a b c d e "CVL 871 - AdisInsight".
- ^ a b Hatzipantelis CJ, Langiu M, Vandekolk TH, Pierce TL, Nithianantharajah J, Stewart GD, Langmead CJ (December 2020). "Translation-Focused Approaches to GPCR Drug Discovery for Cognitive Impairments Associated with Schizophrenia". ACS Pharmacol Transl Sci. 3 (6): 1042–1062. doi:10.1021/acsptsci.0c00117. PMC 7737210. PMID 33344888.
- ^ Wang HJ, Chinna-Meyyappan A, Feldman OJ, Lanctôt KL (June 2024). "Emerging therapies for treatment of agitation, psychosis, or apathy in Alzheimer's disease". Expert Opin Emerg Drugs: 1–15. doi:10.1080/14728214.2024.2363215. PMID 38822731.
- ^ Dolphin H, Dyer AH, McHale C, O'Dowd S, Kennelly SP (July 2023). "An Update on Apathy in Alzheimer's Disease". Geriatrics (Basel). 8 (4): 75. doi:10.3390/geriatrics8040075. PMC 10366907. PMID 37489323.
- ^ "CVL-871 - Cerevel Therapeutics". 2 January 2020.
External links
[edit]